Clinical evaluation of cefamandole nafate.
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D001847:Bone Diseases / Q000188:drug therapy; D002435:Cefamandole / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007592:Joint Diseases / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D013297:Streptococcus pyogenes; D014552:Urinary Tract Infections / Q000188:drug therapy
D002511:Cephalosporins; D002435:Cefamandole